Bainbridge Matthew N, Armstrong Georgina N, Gramatges M Monica, Bertuch Alison A, Jhangiani Shalini N, Doddapaneni Harsha, Lewis Lora, Tombrello Joseph, Tsavachidis Spyros, Liu Yanhong, Jalali Ali, Plon Sharon E, Lau Ching C, Parsons Donald W, Claus Elizabeth B, Barnholtz-Sloan Jill, Il'yasova Dora, Schildkraut Joellen, Ali-Osman Francis, Sadetzki Siegal, Johansen Christoffer, Houlston Richard S, Jenkins Robert B, Lachance Daniel, Olson Sara H, Bernstein Jonine L, Merrell Ryan T, Wrensch Margaret R, Walsh Kyle M, Davis Faith G, Lai Rose, Shete Sanjay, Aldape Kenneth, Amos Christopher I, Thompson Patricia A, Muzny Donna M, Gibbs Richard A, Melin Beatrice S, Bondy Melissa L
Affiliations of authors: Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX (MNB, SNJ, HD, LL, JT, DMM, RAG); Codified Genomics, LLC, Houston, TX (MNB); Department of Pediatrics, Division of Hematology-Oncology, Dan L. Duncan Cancer Center (GNA, MMG, AAB, ST, YL, SEP, CCL, DWP, MLB) and Department of Neurosurgery (AJ), Baylor College of Medicine, Houston, TX; Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT (EBC); Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA (EBC); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH (JBS); Department of Epidemiology and Biostatistics, Georgia State University School of Public Health, Atlanta, GA (DI); Cancer Control and Prevention Program, Department of Community and Family Medicine, Duke University Medical Center, Durham, NC (DI, JS); Department of Surgery, Duke University Medical Center, Durham, North Carolina (FAO); Cancer and Radiation Epidemiology Unit, Gertner Institute, Chaim Sheba Medical Center, Tel Hashomer (SS); Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel (SiS); Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark (CJ); Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK (RSH); Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN (RBJ, DL); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY (SHO, JLB); Department of Neurology, NorthShore University HealthSystem, Evanston, IL (RTM); Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA (MRW, KMW); Department of Public Health Services, University of Alberta, Edmonton, Alberta, Canada (FGD); Departments of Neurology, Neurosurgery, and Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA (RL); Department of Biostatistics (Sa
J Natl Cancer Inst. 2014 Dec 7;107(1):384. doi: 10.1093/jnci/dju384. Print 2015 Jan.
Gliomas are the most common brain tumor, with several histological subtypes of various malignancy grade. The genetic contribution to familial glioma is not well understood. Using whole exome sequencing of 90 individuals from 55 families, we identified two families with mutations in POT1 (p.G95C, p.E450X), a member of the telomere shelterin complex, shared by both affected individuals in each family and predicted to impact DNA binding and TPP1 binding, respectively. Validation in a separate cohort of 264 individuals from 246 families identified an additional mutation in POT1 (p.D617Efs), also predicted to disrupt TPP1 binding. All families with POT1 mutations had affected members with oligodendroglioma, a specific subtype of glioma more sensitive to irradiation. These findings are important for understanding the origin of glioma and could have importance for the future diagnostics and treatment of glioma.
胶质瘤是最常见的脑肿瘤,有几种不同恶性程度的组织学亚型。家族性胶质瘤的遗传因素尚未完全明确。通过对来自55个家庭的90名个体进行全外显子组测序,我们在端粒保护蛋白复合体成员POT1中发现了两个家族存在突变(p.G95C、p.E450X),每个家族中的两名患病个体均携带该突变,预计分别会影响DNA结合和TPP1结合。在来自246个家庭的264名个体的独立队列中进行验证时,又发现了POT1的另一个突变(p.D617Efs),预计也会破坏TPP1结合。所有携带POT1突变的家族中,患病成员均患有少突胶质细胞瘤,这是胶质瘤的一种对放疗更敏感的特定亚型。这些发现对于理解胶质瘤的起源很重要,并且可能对未来胶质瘤的诊断和治疗具有重要意义。